skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration
Executive Summary

According to the National Institutes of Health, 126.1 million adults in the U.S. (or 40.1% of the population) report experiencing some pain in the previous 3 months, with 25.3 million (or 8.1%) suffering from chronic pain and 23.4 million (or 7.4%) reporting high pain levels (Nahin, 2015). According to the American Pain Society, the direct and indirect costs of pain in the U.S. total between $560 billion and $635 billion, with direct healthcare costs accounting for 47% and indirect costs such as lost worker productivity accounting for the remaining 53%. Pain-related costs exceed those of heart disease ($309 billion), cancer ($243 billion), and diabetes ($188 billion) (Gaskin, 2012).

U.S. Markets Approaches to Pain Managment

Multidisciplinary pain management plans may involve the use of pharmacologic, device-based, or alternative therapies; a combination of these modalities often is required to achieve optimal pain relief, particularly for those suffering from chronic pain. A major trend driving the innovation and development of improved pain management treatments in the pain management industry is the demographics of the aging United States (U.S.) population.
U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management Meddevicetracker.
View full report here

Read also

  • Biomedtracker: see the drug development process through anal...

    Q3 2021 Outlook Report

    What major drug catalysts and events can you expect to see in the months ahead? Download your free extract from the Q3 2021 Outlook Report and infographic to find out. Shape your strategy with your inside look at what’s to come.

    Topics Drug Review

    Single Report
;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now